TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target. Issue 3 (23rd April 2019)

• Record Type: Journal Article
• Authors: Chen, Lin‐Yu; Huang, Rui‐Lan; Chan, Michael WY; Yan, Pearlly S; Huang, Tien‐Shuo; Wu, Ren‐Chin; Suryo Rahmanto, Yohan; Su, Po‐Hsuan; Weng, Yu‐Chun; Chou, Jian‐Liang; Chao, Tai‐Kuang; Wang, Yu‐Chi; Shih, Ie‐Ming; Lai, Hung‐Cheng
• Is Part Of: Journal of pathology. Volume 248:Issue 3(2019)
• Page Start: 363
• Page End: 376
• Publication Date: 2019-04-23
• Subjects: casein kinase‐2 -- DNA demethylation -- epigenetics -- epithelial ovarian cancer -- ten‐eleven translocation‐1; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5266
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Ten‐eleven translocation methylcytosine dioxygenase‐1, TET1, takes part in active DNA demethylation. However, our understanding of DNA demethylation in cancer biology and its clinical significance remain limited. This study showed that TET1 expression correlated with poor survival in advanced‐stage epithelial ovarian carcinoma (EOC), and with cell migration, anchorage‐independent growth, cancer stemness, and tumorigenicity. In particular, TET1 was highly expressed in serous tubal intraepithelial carcinoma (STIC), a currently accepted type II EOC precursor, and inversely correlated with TP53 mutations. Moreover, TET1 could demethylate the epigenome and activate multiple oncogenic pathways, including an immunomodulation network having casein kinase II subunit alpha (CK2α) as a hub. Patients with TET1 high CK2α high EOCs had the worst outcomes, and TET1‐expressing EOCs were more sensitive to a CK2 inhibitor, both in vitro and in vivo . Our findings uncover the oncogenic and poor prognostic roles of TET1 in EOC and suggest an unexplored role of epigenetic reprogramming in early ovarian carcinogenesis. Moreover, the immunomodulator CK2α represents a promising new therapeutic target, warranting clinical trials of the tolerable CK2 inhibitor, CX4945, for precision medicine against EOC. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.